A Novel 2-Metagene Signature to Identify High-Risk HNSCC Patients amongst Those Who Are Clinically at Intermediate Risk and Are Treated with PORT.
Patil S, Linge A, Hiepe H, Grosser M, Lohaus F, Gudziol V, Kemper M, Nowak A, Haim D, Tinhofer I, Budach V, Guberina M, Stuschke M, Balermpas P, Grün JV, Schäfer H, Grosu AL, Abdollahi A, Debus J, Ganswindt U, Belka C, Pigorsch S, Combs SE, Boeke S, Zips D, Jöhrens K, Baretton GB, Baumann M, Krause M, Löck S, On Behalf Of The Dktk-Rog.
Patil S, et al. Among authors: grosser m.
Cancers (Basel). 2022 Jun 20;14(12):3031. doi: 10.3390/cancers14123031.
Cancers (Basel). 2022.
PMID: 35740697
Free PMC article.